Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 169-172

  Coutinho, Flavia L ^a   Lourenco, Delmar M ^a   Toledo, Rodrigo A ^a   Montenegro, Fabio L M ^a   Toledo, Sergio P A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bone Mineral Density; MEN1; Parathyroid Hormone; Primary Hyperparathyroidism; Total Parathyroidectomy

Indexed keywords

EID: 84863915514     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)28     Document Type: Review

References (34)

1. Lundgren E, Rastad J, Thrufjell E, Akerström G, Ljunghall S. Populationbased screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997;121:287-94, http://dx.doi.org/10.1016/S0039-6060(97)90357-3.
2. Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, et al. Hyperparathyroidism in hereditary syndromes: special expression and special managements. J Bone Miner Res. 2002;17:37-43.
3. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29:22-32, http://dx.doi.org/10.1002/humu.20605.
4. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA., et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94:340-50, http://dx.doi.org/10.1210/jc.2008-1758.
5. Katai M, Sakurai A, Ikeo Y, Hashizume K. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: comparison with sporadic parathyroid adenomas. Horm Metab Res. 2001;33:499-503, http://dx.doi.org/10.1055/s-2001-16944.
6. Stalberg P, Carling T. familial parathyroid tumors: diagnosis and management. World J Surg. 2009;33:2234-43.
7. Bilezikian JP, Silverberg SJ. Clinical spectrum of primary hyperparathyroidism. Rev Endocr Metab Disord. 2000;1:237-45, http://dx.doi.org/10.1023/A:1026508829397.
8. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247:501-10, http://dx.doi.org/10.1097/SLA.0b013e31815efda5.
9. Toledo RA, Lourenco DM, Coutinho FL, Quedas E, Mackowiack I, Machado MC, et al. Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2007;67:377-84, http://dx.doi.org/10.1111/j.1365-2265.2007.02895.x.
10. Lourenço DM Jr, Toledo RA, Coutinho FL, Margarido LC, Siqueira SA, dos Santos MA, et al. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. Clinics. 2007;62:465-76, http://dx.doi.org/10.1590/S1807-59322007000400014.
11. Costa MH, Domenice S, Toledo RA, Lourenço DM Jr, Latronico AC, Pinto EM, et al. Glucose-dependent insulinotropic peptide receptor overexpression in adrenocortical hyperplasia in MEN1 syndrome without loss of heterozygosity at the 11q13 locus. Clinics. 2011;66:529-33.
12. Thompson NW. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia Type 1 patient. J Intern Med. 1995;238:269-80, http://dx.doi.org/10.1111/j.1365-2796.1995.tb00934.x.
13. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C. et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 type 2. J Clin Endocrinol Metab. 2001;86:5658-71, http://dx.doi.org/10.1210/jc.86.12.5658.
14. Goudet P, Cougard P, Vergès B, Murat A, Carnaille B, Calender A, et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe d'Etude des Néoplasies Endocriniennes Multiples Study Group. World J Surg. 2001;25:886-90.
15. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005;257:27-37, http://dx.doi.org/10.1111/j.1365-2796.2004.01428.x.
16. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg. 2007;246:1075-82, http://dx.doi.org/10.1097/SLA.0b013e31811f4467.
17. Burgess JR, David RB, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism and response to parathyroidectomy. Arch Surg. 1999;134:1119-23, http://dx.doi.org/10.1001/archsurg.134.10.1119.
18. Lourenco DM Jr, Toledo RA, Mackowiak II, Coutinho FL, Cavalcanti MG, Correia-Deur JEM, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features and bone mineral density profile. Eur J Endocrinol. 2008;159:259-74.
19. Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009;24:1404-10, http://dx.doi.org/10.1359/jbmr.090304.
20. Lourenço DM Jr, Coutinho FL, Toledo RA, Montenegro FL, Correia-Deur JE, Toledo SP. Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010;25:2382-91, http://dx.doi.org/10.1002/jbmr.125.
21. Parisien M, Silverberg SJ, Shane E, Cruz L, Lindsay R, Bilezikian JP, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab. 1990;70:930-38, http://dx.doi.org/10.1210/jcem-70-4-930.
22. Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L, et al. Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone 1999;25:237-44.
23. Silverberg SJ, Gartemberg F, Jacobs TP, Shane E, Siris E, Staron RB, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:729-34, http://dx.doi.org/10.1210/jc.80.3.729.
24. Dempster DW, Müller R, Zhou H, Kohler T, Shane E, Parisien M., et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 2007;41:19-24.
25. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008;69:1-19, http://dx.doi.org/10.1111/j.1365-2265.2007.03162.x.
26. Sowa H, Kaji H, Canaff L, Hendy GN, Tsukamoto T, Yamaguchi T, et al. Inactivation of Menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. J Biol Chem. 2003;278:21058-69, http://dx.doi.org/10.1074/jbc.M302044200.
27. Sowa H, Kaji H, Hendy GN, Canaff L, Komori T, Sugimoto T, et al. Menin is required for bone morphogenetic protein 2 and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem. 2004;279:40267-75, http://dx.doi.org/10.1074/jbc.M401312200.
28. Naito J, Kaji H, Sowa H, Hendy GN, Sugimoto T, Chihara K. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. J Biol Chem. 2005;280:4785-91, http://dx.doi.org/10.1074/jbc.M408143200.
29. Kawamata A, Izu Y, Yokoyama H, Amagasa T, Wagner EF, Nakashima K, et al. JunD suppresses bone formation and contributes to low bone mass induced by estrogen depletion. J Cell Biochem. 2008;103:1037-45.
30. Christiansen P, Steiniche T, Mosekilde L, Hessov I, Melsen F. Primary hyperparathyroidism: changes in trabecular bone remodeling following surgical treatment-evaluated by histomorphometric methods. Bone 1990;11:75-79.
31. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with and without parathyroid surgery. N Engl J Med. 1999;3411:1249-55.
32. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93:3462-70, http://dx.doi.org/10.1210/jc.2007-1215.
33. Abdelhadi M, Nordenstrom J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidectomy. J Clin Endocrinol Metab. 1998;83:3845-51, http://dx.doi.org/10.1210/jc.83.11.3845.
34. Coutinho FL, Lourenço DM Jr, Toledo RA, Montenegro FL, Correia-Deur JE, Toledo SP. Bone mineral density analysis in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 after total parathyroidectomy. Clin Endocrinol (Oxf). 2010;72:462-8, http://dx.doi.org/10.1111/j.1365-2265.2009.03672.x.